US-based developer of accessible blood-based liquid biopsy tests that deliver a new way to enhance early cancer detection DELFI Diagnostics, Inc. announced on Monday that it has named Thomas Russo as its new chief financial officer (CFO).
Most recently, Russo has served as CFO of Icosavax, Inc and Assembly Biosciences, and senior finance and commercial operations roles at Gilead Sciences. He has worked as Equity Research Senior Analyst covering biotechnology for Robert W Baird & Co. Inc. He has also served in roles of increasing responsibility within Merck & Co's manufacturing division.
Susan Tousi, DELFI Diagnostics CEO, said, 'Tom has a proven track record of supporting innovators in healthcare, and his combined expertise across biopharma, finance, commercialisation, and the investment community makes him an incredible addition to our growing team of industry visionaries. DELFI is poised to revolutionise cancer screening to better support providers and patients. Tom's appointment expands our capabilities to ensure fiscal excellence, drive adoption at scale, and fulfil the company's potential.'
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment
Hemogenyx Pharmaceuticals announces readiness of FLT3 assay for Phase I Trials at MD Anderson
Avacta announces presentation of updated data on AVA6000 at ESMO Congress 2024